Recombinant FSH Versus HP-HMG for Controled Ovarian Stimulation in Intracitoplasmic Sperm Injection Cycles
Journal
Medical Archives
Date Issued
2011
Author(s)
Zoranco Petanovski
Gligor Dimitrov
Abstract
The aim of this study was to make a conclusion about aplicability of two
differnet gonadothropins in COS (rFSH versus HP-hMG). The primary
conclusion for the success as a result of COS are the mean number of
retrived oocytes, mature oocytes, fertilization rate, mean number of quality
embrios, and criopreverzed embrios. The secondary conclusions were clinical
pregnancy rate and delivery rates. Methods: The study was a retrospective
case–control study,. A total of 1238 fresh, non donor, IVF cycles with COS
were analyzed, but to minimize the bias, only the first cycle for each patient
below 40 yaears old, in that period was analyzed. This selection composed
the group of respondents that was analyzed which in total amounted to 760
patients.( rFSH = 422, HP-hMG = 338). The patients underwent COS by long
luteal protocol using two differnt inducers of COS (rFSH and HP-hMG).
Results: The average starting dose of rFSH used was significantely lower
(152.7±41.1IU), whereas with HMG it was (228.8±68.7 IU, p=000000). The
average number of IU gonadothropin used in therapy, statistically highly is
significantly lower when r- FSH is used as an inducer. (1639.2 ± 476.9 IU,
rFSH vs 2356.4 ± 955.1IU, HP–hMG, p <0.001). We received significantly
higher average number of oocytes and mature oocytes in the group of r–FSH
(oocytes; rFSH v HP-hMG–11.8 ± 7.1 v 10.7 ± 6.5, p = 0.028 ; mature oocytes:
rFSH v HP-hMG 9.9 ± 6.2 v8.7 ± 5.5 p = 0.009). However, we did not find a
significant difference in the use of the COS inductors regarding the clinical
pregnancy rate (rFSH v HP-hMG 49.5% vs 48.9% p=0.92) and delivery rate
(rFSH vs HP-hMG 42.9% vs 43.4% p=0.96). Conclusions: Our study showed
that rFSH is more powerful and more applicable in individualized dosing
then HP-hMG and brings better results from COS (more oocytes, more matured
oocytes). Key words: Controled ovarian stimulation (KOS),
rekominant folikulostimulative hormon (rFSH), high purity
human menopausal gonadothropin (HP-hMG), intracitoplasmic
sperm injection (ICSI), retrived oocytes.
differnet gonadothropins in COS (rFSH versus HP-hMG). The primary
conclusion for the success as a result of COS are the mean number of
retrived oocytes, mature oocytes, fertilization rate, mean number of quality
embrios, and criopreverzed embrios. The secondary conclusions were clinical
pregnancy rate and delivery rates. Methods: The study was a retrospective
case–control study,. A total of 1238 fresh, non donor, IVF cycles with COS
were analyzed, but to minimize the bias, only the first cycle for each patient
below 40 yaears old, in that period was analyzed. This selection composed
the group of respondents that was analyzed which in total amounted to 760
patients.( rFSH = 422, HP-hMG = 338). The patients underwent COS by long
luteal protocol using two differnt inducers of COS (rFSH and HP-hMG).
Results: The average starting dose of rFSH used was significantely lower
(152.7±41.1IU), whereas with HMG it was (228.8±68.7 IU, p=000000). The
average number of IU gonadothropin used in therapy, statistically highly is
significantly lower when r- FSH is used as an inducer. (1639.2 ± 476.9 IU,
rFSH vs 2356.4 ± 955.1IU, HP–hMG, p <0.001). We received significantly
higher average number of oocytes and mature oocytes in the group of r–FSH
(oocytes; rFSH v HP-hMG–11.8 ± 7.1 v 10.7 ± 6.5, p = 0.028 ; mature oocytes:
rFSH v HP-hMG 9.9 ± 6.2 v8.7 ± 5.5 p = 0.009). However, we did not find a
significant difference in the use of the COS inductors regarding the clinical
pregnancy rate (rFSH v HP-hMG 49.5% vs 48.9% p=0.92) and delivery rate
(rFSH vs HP-hMG 42.9% vs 43.4% p=0.96). Conclusions: Our study showed
that rFSH is more powerful and more applicable in individualized dosing
then HP-hMG and brings better results from COS (more oocytes, more matured
oocytes). Key words: Controled ovarian stimulation (KOS),
rekominant folikulostimulative hormon (rFSH), high purity
human menopausal gonadothropin (HP-hMG), intracitoplasmic
sperm injection (ICSI), retrived oocytes.
File(s)![Thumbnail Image]()
Loading...
Name
Recombinant FSH Versus HP.pdf
Size
148.38 KB
Format
Adobe PDF
Checksum
(MD5):abeee4a70079a2725426e7459000d6c0